AkzoNobel stock gets a new JPMorgan Overweight rating

Published on 09/24/2026 at 12:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AkzoNobel stock traded at EUR 57.04 on September 23, 2026, down 0.80 percent with a market value of EUR 11.14 billion. JPMorgan set a EUR 72 target.

Farbenfabrik von Akzo Nobel N.V. an einer Amsterdamer Gracht — Fotorealistische Industrieanlage zeigt Chemiebranche von Akzo Nobel N.V. mit ISIN NL0013267909 an Amsterdamer Gracht, Illustration mit AI erstellt.

AkzoNobel stock (ISIN NL0013267909) closed at EUR 57.04 on Euronext Amsterdam on September 23, 2026, down 0.80 percent from the prior session. On September 24, JPMorgan shifted its rating to Overweight and set a EUR 72 price target, giving the merger story a new valuation reference.

JPMorgan raises the valuation bar

According to finanzen.ch on September 24, 2026, JPMorgan resumed coverage with an Overweight rating and a EUR 72 target. That target stands EUR 14.96 above the September 23 closing price, a concrete gap between the bank view and the market quotation.

The rating change matters because AkzoNobel is preparing a proposed combination with Axalta Coating Systems. The new target puts the analyst case above the stock's latest EUR 57.04 reference price, while the market capitalization stood at EUR 11.14 billion on September 23.

Merger review sets November date

The UK Competition and Markets Authority opened a Phase 1 review of the planned transaction on September 17, 2026. Reuters reported that the review concerns the proposed USD 25 billion merger and whether it could substantially reduce competition in the UK.

The CMA set November 11, 2026, as the deadline for its Phase 1 decision, according to Reuters. The companies have said the transaction could close in late 2026 or early 2027, subject to regulatory approvals and other closing conditions.

Stock stays below EUR 60

AkzoNobel stock remains below the EUR 60 level after the September 23 close, with the daily move at negative 0.80 percent. For investors, the key tension is visible in the figures: the market price was EUR 57.04, while JPMorgan's target was EUR 72.

The valuation debate therefore combines a dated market price, a new bank rating and a regulatory timetable. The next hard checkpoint is November 11, 2026, when the CMA is due to decide whether the merger should proceed to a Phase 2 investigation.